Literature DB >> 17320192

Comparisons of glucose-insulin homeostasis following maprotiline and fluoxetine treatment in depressed males.

Yi-Chyan Chen1, Yu-Chih Shen, Yi-Jen Hung, Chao-Ha Chou, Chin-Bin Yeh, Cheng-Hwang Perng.   

Abstract

BACKGROUND: To investigate the effects of antidepressants on glucose-insulin homeostasis, we provided homogenous situation and performed standard procedures to assess the interactions of antidepressants and glucose regulation during hospitalization.
METHODS: Twenty-three non-diabetic depressed males were recruited and assigned to two groups based on the antidepressants received (maprotiline n=11, fluoxetine n=12). The severity of depression was evaluated using a 21-item Hamilton depression rating scale (HAM-D). Before and after the 4-week treatment, participants underwent 75-g oral glucose tolerance test (OGTT) and frequently sampled intravenous glucose tolerance test (FSIGT). Insulin sensitivity (SI), glucose effectiveness (SG), acute insulin response (AIR), and disposition index (DI) were estimated using minimal model method.
RESULTS: The HAM-D scores were reduced significantly (P<0.005) after antidepressant treatment. Following maprotiline treatment, the body weight and BMI were significantly increased (P=0.02). Individuals treated with maprotiline displayed a significantly increased AIR (3239+/-682 vs. 4698+/-597 pmol; P=0.04) during the FSIGT. LIMITATIONS: The sample size was limited. Furthermore, the study was conducted in the early phase of depression-treated course.
CONCLUSIONS: The results suggest that the beta-cell function is hyperbolic in order to offset the insulin resistance following maprotiline treatment. Our findings imply that norepinephrine reuptake inhibitor (NRI) antidepressants might attenuate insulin sensitivity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17320192     DOI: 10.1016/j.jad.2007.01.023

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  9 in total

Review 1.  The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications.

Authors:  Roger S McIntyre; Ka Young Park; Candy W Y Law; Farah Sultan; Amanda Adams; Maria Teresa Lourenco; Aaron K S Lo; Joanna K Soczynska; Hanna Woldeyohannes; Mohammad Alsuwaidan; Jinju Yoon; Sidney H Kennedy
Journal:  CNS Drugs       Date:  2010-09       Impact factor: 5.749

2.  [Validation of interaction databases in psychopharmacotherapy].

Authors:  M Hahn; S C Roll
Journal:  Nervenarzt       Date:  2018-03       Impact factor: 1.214

Review 3.  Glucose dysregulation associated with antidepressant agents: an analysis of 17 published case reports.

Authors:  Star Khoza; Jamie C Barner
Journal:  Int J Clin Pharm       Date:  2011-04-13

Review 4.  [Depression and diabetes mellitus type 2].

Authors:  M Deuschle; U Schweiger
Journal:  Nervenarzt       Date:  2012-11       Impact factor: 1.214

5.  Antidepressant effects on insulin sensitivity and proinflammatory cytokines in the depressed males.

Authors:  Yi-Chyan Chen; Wei-Win Lin; Yu-Jung Chen; Wei-Chung Mao; Yi-Jen Hung
Journal:  Mediators Inflamm       Date:  2010-05-18       Impact factor: 4.711

6.  Acute psychological stress results in the rapid development of insulin resistance.

Authors:  Li Li; Xiaohua Li; Wenjun Zhou; Joseph L Messina
Journal:  J Endocrinol       Date:  2013-04-15       Impact factor: 4.286

7.  A high-throughput chemical-genetics screen in murine adipocytes identifies insulin-regulatory pathways.

Authors:  Paul Duffield Brewer; Irina Romenskaia; Cynthia Corley Mastick
Journal:  J Biol Chem       Date:  2018-12-27       Impact factor: 5.157

8.  Depression, depression treatment, and insulin sensitivity in adults at risk for type 2 diabetes.

Authors:  Julie Wagner; Nancy A Allen; Leah M Swalley; Gail D Melkus; Robin Whittemore
Journal:  Diabetes Res Clin Pract       Date:  2009-08-31       Impact factor: 5.602

9.  Fluoxetine regulates glucose and lipid metabolism via the PI3K‑AKT signaling pathway in diabetic rats.

Authors:  Hailong Yang; Qiuyun Cao; Xiaolu Xiong; Peng Zhao; Diwen Shen; Yuzhe Zhang; Ning Zhang
Journal:  Mol Med Rep       Date:  2020-08-04       Impact factor: 2.952

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.